Opiate addiction and cocaine addiction: Underlying molecular neurobiology and genetics

Journal of Clinical Investigation

Volumn 122, Issue 10, 2012, Pages 3387-3391

  Kreek, Mary Jeanne ^a   Levran, Orna ^a   Reed, Brian ^a   Schlussman, Stefan D ^a   Zhou, Yan ^a   Butelman, Eduardo R ^a  

^a ROCKEFELLER UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COCAINE; DIAMORPHINE; DOPAMINE; METHADONE; NALTREXONE; OPIATE;

BEHAVIOR GENETICS; COCAINE DEPENDENCE; DRUG EFFICACY; GENETIC VARIABILITY; HEROIN DEPENDENCE; HUMAN; MAINTENANCE THERAPY; NEUROBIOLOGY; NONHUMAN; OPIATE ADDICTION; PHARMACOGENETICS; PRIORITY JOURNAL; REVIEW; STRESS; TREATMENT RESPONSE;

ANIMALS; BASAL GANGLIA; COCAINE-RELATED DISORDERS; DOPAMINE; DOPAMINERGIC NEURONS; GENE EXPRESSION REGULATION; GENETIC PREDISPOSITION TO DISEASE; HUMANS; HYPOTHALAMO-HYPOPHYSEAL SYSTEM; LIMBIC SYSTEM; METHADONE; MICE; MICE, KNOCKOUT; NEUROPEPTIDES; OPIOID-RELATED DISORDERS; PHARMACOGENETICS; PITUITARY-ADRENAL SYSTEM; RATS; RECEPTORS, DOPAMINE; RECEPTORS, OPIOID; RECEPTORS, OPIOID, MU; REWARD; STRESS, PHYSIOLOGICAL; STRESS, PSYCHOLOGICAL;

EID: 84867164588     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI60390     Document Type: Review

References (124)

1. Dole VP, Nyswander ME, Kreek MJ. Narcotic blockade. Arch Intern Med. 1966;118(4):304-309.
2. Kreek MJ. Medical safety and side effects of methadone in tolerant individuals. JAMA. 1973;223(6):665-668.
3. Kreek MJ. Methadone-related opioid agonist pharmacotherapy for heroin addiction. History, recent molecular and neurochemical research and future in mainstream medicine. Ann N Y Acad Sci. 2000;909:186-216. (Pubitemid 30462040)
4. Novick DM, Khan I, Kreek MJ. Acquired immunodeficiency syndrome and infection with hepatitis viruses in individuals abusing drugs by injection. Bull Narc. 1986;38(1-2):15-25.
5. Di Chiara G, Imperato A. Drugs abused by humans preferentially increase synaptic dopamine concentrations in the mesolimbic system of freely moving rats. Proc Natl Acad Sci U S A. 1988;85(14):5274-5278.
6. Maisonneuve IM, Kreek MJ. Acute tolerance to the dopamine response induced by a binge pattern of cocaine administration in male rats: an in vivo microdialysis study. J Pharmacol Exp Ther. 1994;268(2):916-921. (Pubitemid 24085894)
7. Pettit HO, Ettenberg A, Bloom FE, Koob GF. Destruction of dopamine in the nucleus accumbens selectively attenuates cocaine but not heroin self-administration in rats. Psychopharmacology (Berl). 1984;84(2):167-173. (Pubitemid 14006568)
8. Tsukada H, et al. Effects of binge pattern cocaine administration on dopamine D1 and D2 receptors in the rat brain: an in vivo study using positron emission tomography. J Neurosci. 1996;16(23):7670-7677. (Pubitemid 26389706)
9. Spangler R, Zhou Y, Maggos CE, Zlobin A, Ho A, Kreek MJ. Dopamine antagonist and ''binge' cocaine effects on rat opioid and dopamine transporter mRNAs. Neuroreport. 1996;7(13):2196-2200. (Pubitemid 26361845)
10. Volkow ND, et al. Effects of chronic cocaine abuse on postsynaptic dopamine receptors. Am J Psychiatry. 1990;147(6):719-724. (Pubitemid 20188509)
11. Zhou Y, Leri F, Cummins E, Hoeschele M, Kreek MJ. Involvement of arginine vasopressin and V1b receptor in heroin withdrawal and heroin seeking precipitated by stress and by heroin. Neuropsychopharmacology. 2008;33(2):226-236. (Pubitemid 350243360)
12. Zhou Y, Bendor J, Hofmann L, Randesi M, Ho A, Kreek MJ. Mu opioid receptor and orexin/hypocretin mRNA levels in the lateral hypothalamus and striatum are enhanced by morphine withdrawal. J Endocrinol. 2006;191(1):137-145. (Pubitemid 44756516)
13. Hall FS, Sora I, Uhl GR. Ethanol consumption and reward are decreased in mu-opiate receptor knockout mice. Psychopharmacology (Berl). 2001;154(1):43-49. (Pubitemid 32186514)
14. Peng X, Knapp BI, Bidlack JM, Neumeyer JL. Pharmacological properties of bivalent ligands containing butorphan linked to nalbuphine, naltrexone, and naloxone at mu, delta, and kappa opioid receptors. J Med Chem. 2007;50(9):2254-2258. (Pubitemid 46683079)
15. O'Malley SS, Krishnan-Sarin S, Farren C, Sinha R, Kreek MJ. Naltrexone decreases craving and alcohol self-administration in alcohol-dependent subjects and activates the hypothalamo-pituitary-adrenocortical axis. Psychopharmacology (Berl). 2002;160(1):19-29. (Pubitemid 34169822)
16. Fox HC, Talih M, Malison R, Anderson GM, Kreek MJ, Sinha R. Frequency of recent cocaine and alcohol use affects drug craving and associated responses to stress and drug-related cues. Psychoneuroendocrinology. 2005;30(9):880-891. (Pubitemid 40977910)
17. Schluger JH, Bart G, Green M, Ho A, Kreek MJ. Corticotropin-releasing factor testing reveals a dose-dependent difference in methadone maintained vs control subjects. Neuropsychopharmacology. 2003;28(5):985-994.
18. Schluger JH, Borg L, Ho A, Kreek MJ. Altered HPA axis responsivity to metyrapone testing in methadone maintained former heroin addicts with ongoing cocaine addiction. Neuropsychopharmacology. 2001;24(5):568-575. (Pubitemid 32244317)
19. Maisonneuve IM, Ho A, Kreek MJ. Chronic administration of a cocaine "binge" alters basal extracellular levels in male rats: an in vivo microdialysis study. J Pharmacol Exp Ther. 1995;272(2):652-657.
20. Zhang Y, Schlussman SD, Ho A, Kreek MJ. Effect of acute binge cocaine on levels of extracellular dopamine in the caudate putamen and nucleus accumbens in male C57BL/6J and 129/J mice. Brain Res. 2001;923(1-2):172-177. (Pubitemid 34024949)
21. Zhang Y, Schlussman SD, Ho A, Kreek MJ. Effect of chronic "binge cocaine" on basal levels and cocaine-induced increases of dopamine in the caudate putamen and nucleus accumbens of C57BL/6J and 129/J mice. Synapse. 2003;50(3):191-199. (Pubitemid 37315349)
22. Di Chiara G, Imperato A. Opposite effects of mu and kappa opiate agonists on dopamine release in the nucleus accumbens and in the dorsal caudate of freely moving rats. J Pharmacol Exp Ther. 1988;244(3):1067-1080. (Pubitemid 18090131)
23. Zhang Y, Picetti R, Butelman ER, Schlussman SD, Ho A, Kreek MJ. Behavioral and neurochemical changes induced by oxycodone differ between adolescent and adult mice. Neuropsychopharmacology. 2009;34(4):912-922.
24. Spanagel R, Herz A, Shippenberg TS. The effects of opioid peptides on dopamine release in the nucleus accumbens: an in vivo microdialysis study. J Neurochem. 1990;55(5):1734-1740.
25. Zhang Y, Butelman ER, Schlussman SD, Ho A, Kreek MJ. Effect of the endogenous kappa opioid agonist dynorphin A(1-17) on cocaine-evoked increases in striatal dopamine levels and cocaine-induced place preference in C57BL/6J mice. Psychopharmacology (Berl). 2004;172(4):422-429. (Pubitemid 38650978)
26. Unterwald EM, Horne-King J, Kreek MJ. Chronic cocaine alters brain mu opioid receptors. Brain Res. 1992;584(1-2):314-318.
27. Unterwald EM, Rubenfeld JM, Kreek MJ. Repeated cocaine administration upregulates kappa and mu, but not delta, opioid receptors. Neuroreport. 1994;5(13):1613-1616. (Pubitemid 24265254)
28. Bailey A, Gianotti R, Ho A, Kreek MJ. Downregulation of kappa-opioid receptors in basolateral amygdala and septum of rats withdrawn for 14 days from an escalating dose "binge" cocaine administration paradigm. Synapse. 2007;61(10):820-826. (Pubitemid 47328800)
29. Bailey A, Gianotti R, Ho A, Kreek MJ. Persistent upregulation of mu-opioid, but not adenosine, receptors in brains of long-term withdrawn escalating dose "binge" cocaine-treated rats. Synapse. 2005;57(3):160-166. (Pubitemid 41023472)
30. Zubieta JK, Gorelick DA, Stauffer R, Ravert HT, Dannals RF, Frost JJ. Increased mu opioid receptor binding detected by PET in cocaine-dependent men is associated with cocaine craving. Nat Med. 1996;2(11):1225-1229. (Pubitemid 26375406)
31. Leri F, Zhou Y, Goddard B, Cummins E, Kreek MJ. Effects of high-dose methadone maintenance on cocaine place conditioning, cocaine self-administration, and mu-opioid receptor mRNA expression in the rat brain. Neuropsychopharmacology. 2006;31(7):1462-1474.
32. Leri F, Zhou Y, Goddard B, Levy A, Jacklin D, Kreek MJ. Steady-state methadone blocks cocaine seeking and cocaine-induced gene expression alterations in the rat brain. Eur Neuropsychopharmacol. 2009;19(4):238-249.
33. Peles E, Kreek MJ, Kellogg S, Adelson M. High methadone dose significantly reduces cocaine use in methadone maintenance treatment (MMT) patients. J Addict Dis. 2006;25(1):43-50. (Pubitemid 43673090)
34. Montoya ID, et al. Randomized trial of buprenorphine for treatment of concurrent opiate and cocaine dependence. Clin Pharmacol Ther. 2004;75(1):34-48.
35. Ahmadi J, Kampman KM, Oslin DM, Pettinati HM, Dackis C, Sparkman T. Predictors of treatment outcome in outpatient cocaine and alcohol dependence treatment. Am J Addict. 2009;18(1):81-86.
36. Jayaram-Lindstrom N, Hammarberg A, Beck O, Franck J. Naltrexone for the treatment of amphetamine dependence: a randomized, placebo-controlled trial. Am J Psychiatry. 2008;165(11):1442-1448.
37. Beardsley PM, Howard JL, Shelton KL, Carroll FI. Differential effects of the novel kappa opioid receptor antagonist, JDTic, on reinstatement of cocaine-seeking induced by footshock stressors vs cocaine primes and its antidepressant-like effects in rats. Psychopharmacology (Berl). 2005;183(1):118-126. (Pubitemid 41484188)
38. Chefer VI, Czyzyk T, Bolan EA, Moron J, Pintar JE, Shippenberg TS. Endogenous kappa-opioid receptor systems regulate mesoaccumbal dopamine dynamics and vulnerability to cocaine. J Neurosci. 2005;25(20):5029-5037. (Pubitemid 40712846)
39. Redila VA, Chavkin C. Stress-induced reinstatement of cocaine seeking is mediated by the kappa opioid system. Psychopharmacology (Berl). 2008;200(1):59-70.
40. Kreek MJ, LaForge KS, Butelman E. Pharmacotherapy of addictions. Nat Rev Drug Discov. 2002;1(9):710-726. (Pubitemid 37361544)
41. Zhu BT. Mechanistic explanation for the unique pharmacologic properties of receptor partial agonists. Biomed Pharmacother. 2005;59(3):76-89. (Pubitemid 40417517)
42. Chartoff E, Sawyer A, Rachlin A, Potter D, Pliakas A, Carlezon WA. Blockade of kappa opioid receptors attenuates the development of depressive-like behaviors induced by cocaine withdrawal in rats. Neuropharmacology. 2012;62(1):167-176.
43. Johnston LD, O'Malley PM, Bachman JG, Schulenberg JE. Monitoring The Future National Survey Results On Drug Use, 1975-2010. Vol. 1: Secondary School Students. Ann Arbor, Michigan, USA: Institute for Social Research, The University of Michigan; 2011.
44. McCabe SE, West BT, Teter CJ, Boyd CJ. Medical and nonmedical use of prescription opioids among high school seniors in the United States [published online ahead of print May 7, 2012]. Arch Pediatr Adolesc Med. doi:10.1001/archpediatrics.2012.85.
45. Inturrisi CE, Schultz M, Shin S, Umans JG, Angel L, Simon EJ. Evidence from opiate binding studies that heroin acts through its metabolites. Life Sci. 1983;33(suppl 1):773-776. (Pubitemid 14202648)
46. Johnson SW, North RA. Opioids excite dopamine neurons by hyperpolarization of local interneurons. J Neurosci. 1992;12(2):483-488.
47. Schlussman SD, Cassin J, Zhang Y, Levran O, Ho A, Kreek MJ. Regional mRNA expression of the endogenous opioid and dopaminergic systems in brains of C57BL/6J and 129P3/J mice: strain and heroin effects. Pharmacol Biochem Behav. 2011;100(1):8-16.
48. Turchan J, Przew?ocka B, Toth G, Lason W, Borsodi A, Przew?ocki R. The effect of repeated administration of morphine, cocaine and ethanol on mu and delta opioid receptor density in the nucleus accumbens and striatum of the rat. Neuroscience. 1999;91(3):971-977. (Pubitemid 29225628)
49. Turchan J, Lason W, Budziszewska B, Przewlocka B. Effects of single and repeated morphine administration on the prodynorphin, proenkephalin and dopamine D2 receptor gene expression in the mouse brain. Neuropeptides. 1997;31(1):24-28. (Pubitemid 27112610)
50. Beitner-Johnson D, Nestler EJ. Morphine and cocaine exert common chronic actions on tyrosine hydroxylase in dopaminergic brain reward regions. J Neurochem. 1991;57(1):344-347.
51. Picetti R, Caccavo JA, Ho A, Kreek MJ. Dose escalation and dose preference in extended-access heroin self-administration in Lewis and Fischer rats. Psychopharmacology (Berl). 2012;220(1):163-172.
52. Gieryk A, Ziolkowska B, Solecki W, Kubik J, Przewlocki R. Forebrain PENK and PDYN gene expression levels in three inbred strains of mice and their relationship to genotype-dependent morphine reward sensitivity. Psychopharmacology (Berl). 2010;208(2):291-300.
53. Zhang Y, et al. Mu opioid receptor knockdown in the substantia nigra/ventral tegmental area by synthetic small interfering RNA blocks the rewarding and locomotor effects of heroin. Neuroscience. 2009;158(2):474-483.
54. Sinha R, Garcia M, Paliwal P, Kreek MJ, Rounsaville BJ. Stress-induced cocaine craving and hypothalamic-pituitary-adrenal responses are predictive of cocaine relapse outcomes. Arch Gen Psychiatry. 2006;63(3):324-331. (Pubitemid 43345357)
55. Vale W, Spiess J, Rivier C, Rivier J. Characterization of a 41-residue ovine hypothalamic peptide that stimulates secretion of corticotropin and betaendorphin. Science. 1981;213(4514):1394-1397. (Pubitemid 12243637)
56. Zhou Y, Litvin Y, Piras AP, Pfaff DW, Kreek MJ. Persistent Increase in hypothalamic arginine vasopressin gene expression during protracted withdrawal from chronic escalating-dose cocaine in rodents. Neuropsychopharmacol. 2011;36(10):2062-2075.
57. Zhou Y, et al. Hypothalamic-pituitary-adrenal activity and pro-opiomelanocortin mRNA levels in the hypothalamus and pituitary of the rat are differentially modulated by acute intermittent morphine with or without water restriction stress. J Endocrinol. 1999;163(2):261-267.
58. Kreek MJ, Ragunath J, Plevy S, Hamer D, Schneider B, Hartman N. ACTH, cortisol and beta-endorphin response to metyrapone testing during chronic methadone maintenance treatment in humans. Neuropeptides. 1984;5(1-3):277-278. (Pubitemid 15163382)
59. Zhou Y, Spangler R, Maggos CE, LaForge KS, Ho A, Kreek MJ. Steady-state methadone in rats does not change mRNA levels of corticotropin-releasing factor, its pituitary receptor or proopiomelanocortin. Eur J Pharmacol. 1996;315(1):31-35. (Pubitemid 26390946)
60. Leri F, Zhou Y, Carmichael B, Cummins E, Kreek MJ. Treatment-like steady-state methadone in rats interferes with incubation of cocaine sensitization and associated alterations in gene expression. Eur Neuropsychopharmacol. 2012;22(2):143-152.
61. Ignar DM, Kuhn CM. Effects of specific mu and kappa opiate tolerance and abstinence on hypothalamo-pituitary-adrenal axis secretion in the rat. J Pharmacol Exp Ther. 1990;255(3):1287-1295.
62. Mendelson JH, Sholar M, Mello NK, Teoh SK, Sholar JW. Cocaine tolerance: behavioral, cardiovascular, and neuroendocrine function in men. Neuropsychopharmacology. 1998;18(4):263-271. (Pubitemid 28085525)
63. Wilkins JN, et al. DHEAS and POMS measures identify cocaine dependence treatment outcome. Psychoneuroendocrinology. 2005;30(1):18-28. (Pubitemid 39195041)
64. Brady KT, et al. Response to corticotropin-releasing hormone infusion in cocaine-dependent individuals. Arch Gen Psychiatry. 2009;66(4):422-430.
65. Zhou Y, Spangler R, LaForge KS, Maggos CE, Ho A, Kreek MJ. Corticotropin-releasing factor and type 1 corticotropin-releasing factor receptor messenger RNAs in rat brain and pituitary during "binge"- pattern cocaine administration and chronic withdrawal. J Pharmacol Exp Ther. 1996;279(1):351-358.
66. Spangler R, Zhou Y, Schlussman SD, Ho A, Kreek MJ. Behavioral stereotypies induced by ''binge' cocaine administration are independent of drug-induced increases in corticosterone levels. Behav Brain Res. 1997;86(2):201-204. (Pubitemid 27154264)
67. Rivier C, Vale W. Cocaine stimulates adrenocorticotropin (ACTH) secretion through a corticotropinreleasing factor (CRF)-mediated mechanism. Brain Res. 1987;422(2):403-406. (Pubitemid 18024051)
68. Zhou Y, Spangler R, Ho A, Kreek MJ. Increased CRH mRNA levels in the rat amygdala during short-term withdrawal from chronic 'binge' cocaine. Brain Res Mol Brain Res. 2003;114(1):73-79. (Pubitemid 36627998)
69. Zhou Y, Spangler R, Schlussman SD, Ho A, Kreek MJ. Alterations in hypothalamic-pituitary-adrenal axis activity and in levels of proopiomelanocortin and corticotropin-releasing hormone-receptor 1 mRNAs in the pituitary and hypothalamus of the rat during chronic 'binge' cocaine and withdrawal. Brain Res. 2003;964(2):187-199. (Pubitemid 36165143)
70. Weiss F. Neurobiology of craving, conditioned reward and relapse. Curr Opin Pharmacol. 2005;5(1):9-19. (Pubitemid 40124529)
71. Kreek MJ, Koob GF. Drug dependence: stress and dysregulation of brain reward pathways. Drug Alcohol Depend. 1998;51(1-2):23-47. (Pubitemid 28353754)
72. Shaham Y, Erb S, Stewart J. Stress-induced relapse to heroin and cocaine seeking in rats: a review. Brain Res Brain Res Rev. 2000;33(1):13-33.
73. Lolait SJ, et al. Extrapituitary expression of the rat V1b vasopressin receptor gene. Proc Natl Acad Sci U S A. 1995;92(15):6783-6787.
74. Griebel G, et al. Anxiolytic- and antidepressant-like effects of the non-peptide vasopressin V1b receptor antagonist, SSR149415, suggest an innovative approach for the treatment of stress-related disorders. Proc Natl Acad Sci U S A. 2002;99(9):6370-6375. (Pubitemid 34493318)
75. Zhou Y, Bendor JT, Yuferov V, Schlussman SD, Ho A, Kreek MJ. Amygdalar vasopressin mRNA increases in acute cocaine withdrawal: evidence for opioid receptor modulation. Neuroscience. 2005;134(4):1391-1397. (Pubitemid 41207386)
76. Zhou Y, Colombo G, Carai MA, Ho A, Gessa GL, Kreek MJ. Involvement of arginine vasopressin and V1b receptor in alcohol drinking in Sardinian alcohol-preferring rats. Alcohol Clin Exp Res. 2011;35(10):1876-1883.
77. Spanagel R, Herz A, Bals-Kubik R, Shippenberg TS. Beta-endorphin-induced locomotor stimulation and reinforcement are associated with an increase in dopamine release in the nucleus accumbens. Psychopharmacology (Berl). 1991;104(1):51-56.
78. Koob G, Kreek MJ. Stress, dysregulation of drug reward pathways, and the transition to drug dependence. Am J Psychiatry. 2007;164(8):1149-1159. (Pubitemid 47292402)
79. Houdi AA, Bardo MT, Van Loon GR. Opioid mediation of cocaine-induced hyperactivity and reinforcement. Brain Res. 1989;497(1):195-198. (Pubitemid 19219930)
80. Ramsey NF, van Ree JM. Intracerebroventricular naltrexone treatment attenuates acquisition of intravenous cocaine self-administration in rats. Pharmacol Biochem Behav. 1991;40(4):807-810.
81. Marquez P, Baliram R, Dabaja I, Gajawada N, Lutfy K. The role of beta-endorphin in the acute motor stimulatory and rewarding actions of cocaine in mice. Psychopharmacology (Berl). 2008;197(3):443-448.
82. Kreek MJ, Bart G, Lilly C, LaForge KS, Nielsen DA. Pharmacogenetics and human molecular genetics of opiate and cocaine addictions and their treatments. Pharmacol Rev. 2005;57(1):1-26. (Pubitemid 40283968)
83. Yuferov V, Levran O, Proudnikov D, Nielsen DA, Kreek MJ. Search for genetic markers and functional variants involved in the development of opiate and cocaine addiction and treatment. Ann N Y Acad Sci. 2010;1187:184-207.
84. Levran O, Yuferov V, Kreek MJ. The genetics of the opioid system and specific drug addictions. Hum Genet. 2012;131(6):823-842.
85. Bond C, et al. Single-nucleotide polymorphism in the human mu opioid receptor gene alters beta-endorphin binding and activity: possible implications for opiate addiction. Proc Natl Acad Sci U S A. 1998;95(16):9608-9613. (Pubitemid 28506279)
86. Deb I, Chakraborty J, Gangopadhyay PK, Choudhury SR, Das S. Single-nucleotide polymorphism (A118G) in exon 1 of OPRM1 gene causes alteration in downstream signaling by mu-opioid receptor and may contribute to the genetic risk for addiction. J Neurochem. 2010;112(2):486-496.
87. Zhang Y, Wang D, Johnson AD, Papp AC, Sadee W. Allelic expression imbalance of human mu opioid receptor (OPRM1) caused by variant A118G. J Biol Chem. 2005;280(38):32618-32624. (Pubitemid 41368304)
88. Beyer A, Koch T, Schroder H, Schulz S, Hollt V. Effect of the A118G polymorphism on binding affinity, potency and agonist-mediated endocytosis, desensitization, and resensitization of the human mu-opioid receptor. J Neurochem. 2004;89(3):553-560. (Pubitemid 38534141)
89. Kroslak T, Laforge KS, Gianotti RJ, Ho A, Nielsen DA, Kreek MJ. The single nucleotide polymorphism A118G alters functional properties of the human mu opioid receptor. J Neurochem. 2007;103(1):77-87. (Pubitemid 47404205)
90. Mague SD, Isiegas C, Huang P, Liu-Chen LY, Lerman C, Blendy JA. Mouse model of OPRM1 (A118G) polymorphism has sex-specific effects on drug-mediated behavior. Proc Natl Acad Sci U S A. 2009;106(26):10847-10852.
91. Huang P, Chen C, Mague SD, Blendy JA, Liu-Chen LY. A common single nucleotide polymorphism A118G of the mu opioid receptor alters its N-glycosylation and protein stability. Biochem J. 2012;441(1):379-386.
92. Ramchandani VA, et al. A genetic determinant of the striatal dopamine response to alcohol in men. Mol Psychiatry. 2011;16(8):809-817.
93. Mague SD, Blendy JA. OPRM1 SNP (A118G): involvement in disease development, treatment response, and animal models. Drug Alcohol Depend. 2010;108(3):172-182.
94. Ray LA, Barr CS, Blendy JA, Oslin D, Goldman D, Anton RF. The role of the Asn40Asp polymorphism of the mu opioid receptor gene (OPRM1) on alcoholism etiology and treatment: A critical review. Alcohol Clin Exp Res. 2012;36(3):385-394.
95. Bart G, et al. Substantial attributable risk related to a functional mu-opioid receptor gene polymorphism in association with heroin addiction in central Sweden. Mol Psychiatry. 2004;9(6):547-549.
96. Bart G, et al. Increased attributable risk related to a functional mu-opioid receptor gene polymorphism in association with alcohol dependence in central Sweden. Neuropsychopharmacology. 2005;30(2):417-422. (Pubitemid 40129493)
97. Oertel BG, et al. A common human micro-opioid receptor genetic variant diminishes the receptor signaling efficacy in brain regions processing the sensory information of pain. J Biol Chem. 2009;284(10):6530-6535.
98. Kapur S, Sharad S, Singh RA, Gupta AK. A118g polymorphism in mu opioid receptor gene (oprm1): association with opiate addiction in subjects of Indian origin. J Integr Neurosci. 2007;6(4):511-522.
99. Glatt SJ, et al. Evaluation of OPRM1 variants in heroin dependence by family-based association testing and meta-analysis. Drug Alcohol Depend. 2007;90(2-3):159-165. (Pubitemid 47299168)
100. Levran O, Awolesi O, Linzy S, Adelson M, Kreek MJ. Haplotype block structure of the genomic region of the mu opioid receptor gene. J Hum Genet. 2011;56(2):147-155.
101. Sturgess JE, George TP, Kennedy JL, Heinz A, Muller DJ. Pharmacogenetics of alcohol, nicotine and drug addiction treatments. Addict Biol. 2011;16(3):357-376.
102. Chong RY, Oswald L, Yang X, Uhart M, Lin PI, Wand GS. The mu-opioid receptor polymorphism A118G predicts cortisol responses to naloxone and stress. Neuropsychopharmacology. 2006;31(1):204-211. (Pubitemid 43250957)
103. Hernandez-Avila CA, Wand G, Luo X, Gelernter J, Kranzler HR. Association between the cortisol response to opioid blockade and the Asn40Asp polymorphism at the mu-opioid receptor locus (OPRM1). Am J Med Genet B Neuropsychiatr Genet. 2003;118B(1):60-65. (Pubitemid 37064077)
104. Wand GS, et al. The mu-opioid receptor gene polymorphism (A118G) alters HPA axis activation induced by opioid receptor blockade. Neuropsychopharmacology. 2002;26(1):106-114. (Pubitemid 34075281)
105. Hernandez-Avila CA, Covault J, Wand G, Zhang H, Gelernter J, Kranzler HR. Population-specific effects of the Asn40Asp polymorphism at the mu-opioid receptor gene (OPRM1) on HPA-axis activation. Pharmacogenet Genomics. 2007;17(12):1031-1038. (Pubitemid 351339487)
106. Ducat E, et al. Mu-opioid receptor A118G polymorphism in healthy volunteers affects hypothalamic-pituitary-adrenal axis adrenocorticotropic hormone stress response to metyrapone [published online ahead of print April 20, 2011]. Addict Biol. doi:10.1111/j.1369-1600.2011.00313.x.
107. Shi Q, Cleeland CS, Klepstad P, Miaskowski C, Pedersen NL. Biological pathways and genetic variables involved in pain. Qual Life Res. 2010;19(10):1407-1417.
108. Crystal HA, et al. A C17T polymorphism in the mu opiate receptor is associated with quantitative measures of drug use in African American women. Addict Biol. 2012;17(1):181-191.
109. Levran O, et al. Genetic susceptibility to heroin addiction: a candidate gene association study. Genes Brain Behav. 2008;7(7):720-729.
110. Zhang H, et al. Association between two mu-opioid receptor gene (OPRM1) haplotype blocks and drug or alcohol dependence. Hum Mol Genet. 2006;15(6):807-819. (Pubitemid 43338224)
111. Zhang D, et al. Effect of mu-opioid receptor gene polymorphisms on heroin-induced subjective responses in a Chinese population. Biol Psychiatry. 2007;61(11):1244-1251. (Pubitemid 46726256)
112. Nielsen DA, et al. Genotype patterns that contribute to increased risk for or protection from developing heroin addiction. Mol Psychiatry. 2008;13(4):417-428. (Pubitemid 351399824)
113. Levran O, et al. ABCB1 (MDR1) genetic variants are associated with methadone doses required for effective treatment of heroin dependence. Hum Mol Genet. 2008;17(14):2219-2227. (Pubitemid 351916578)
114. Levran O, Peles E, Hamon S, Randesi M, Adelson M, Kreek MJ. CYP2B6 SNPs are associated with methadone dose required for effective treatment of opioid addiction [published online ahead of print July 25, 2011]. Addict Biol. doi:10.1111/j.1369-1600.2011.00349.x.
115. Levran O, et al. Nerve growth factor beta polypeptide (NGFB) genetic variability: association with the methadone dose required for effective maintenance treatment. Pharmacogenomics J. 2012;12(4):319-327.
116. Kreek MJ. Role of a functional human gene polymorphism in stress responsivity and addictions. Clin Pharmacol Ther. 2008;83(4):615-618. (Pubitemid 351417078)
117. Hung CC, et al. Impact of genetic polymorphisms in ABCB1, CYP2B6, OPRM1, ANKK1 and DRD2 genes on methadone therapy in Han Chinese patients. Pharmacogenomics. 2011;12(11):1525-1533.
118. Oneda B, et al. β-Arrestin2 influences the response to methadone in opioid-dependent patients. Pharmacogenomics J. 2011;11(4):258-266.
119. de Cid R, et al. BDNF variability in opioid addicts and response to methadone treatment: preliminary findings. Genes Brain Behav. 2008;7(5):515-522.
120. Fonseca F, et al. Contribution of cytochrome P450 and ABCB1 genetic variability on methadone pharmacokinetics, dose requirements, and response. PLoS One. 2011;6(5):e19527.
121. Doehring A, et al. Genetic variants altering dopamine D2 receptor expression or function modulate the risk of opiate addiction and the dosage requirements of methadone substitution. Pharmacogenet Genomics. 2009;19(6):407-414.
122. Lawford BR, et al. The D(2) dopamine receptor A(1) allele and opioid dependence: association with heroin use and response to methadone treatment. Am J Med Genet. 2000;96(5):592-598.
123. Fonseca F, et al. Response to methadone maintenance treatment is associated with the MYOCD and GRM6 genes. Mol Diagn Ther. 2010;14(3):171-178.
124. Lotsch J, Pruss H, Veh RW, Doehring A. A KCNJ6 (Kir3.2, GIRK2) gene polymorphism modulates opioid effects on analgesia and addiction but not on pupil size. Pharmacogenet Genomics. 2010;20(5):291-297.